Bipolar Disorder (2018) |
1.74 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ADD3 STK4 |
Bipolar Disorder or Schizophrenia |
2.31 |
9 |
6 |
13.3 |
0.54 |
1.3e-01 |
ACTR1A C2orf82 FTSJ2 MGAT3 MPHOSPH9 MPP6 RP11-261C10.5 ST3GAL3 STK4 |
Depressed Affect (Nagel 2018) |
3.11 |
13 |
6 |
13.3 |
-0.80 |
5.6e-04 |
CELF2 CELF4 DND1 GALNT16 GPX1 JMJD1C-AS1 LINC00461 MST1R RABGAP1L RBM6 RNF123 RP11-261C10.5 TANK |
Depression (Nagel 2018) |
1.87 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
JMJD1C-AS1 |
Intelligence (Savage-Jansen 2018) |
7.12 |
56 |
37 |
82.2 |
0.98 |
8.6e-41 |
ACTR1A AFF3 BNIP3 CALN1 CAMKMT CEP57 CKM COX6B1 CTD-3025N20.2 CYHR1 DCAF16 DNAH11 DND1 DOT1L EFTUD1 EIF3CL ELOVL7 FAM160A1 FBXO41 FOXO3 FOXO6 FOXP1 GNL3LP1 GPX1 HYI IFT57 IST1 JMJD1C-AS1 JUND LINC00461 LMOD1 LONRF2 MAN2A1 MGAT3 MPHOSPH9 MST1R NEGR1 NOVA1 NPM3 NR2F1-AS1 PPA2 PPP2R2D RABGAP1L RBL2 RBM6 RNF123 RP11-1186N24.5 RPS26 SNX29 ST3GAL3 ST6GAL2 SYPL2 TANK TEX15 TRAIP TRMT61A |
Neuroticism (Nagel 2018) |
2.32 |
11 |
4 |
8.9 |
-0.69 |
1.9e-02 |
B3GALTL CELF2 CELF4 CTC-498M16.2 DND1 FTSJ2 GALNT16 GATC LINC00461 STK24 THEM6 |
Schizophrenia (2018) |
2.44 |
7 |
2 |
4.4 |
0.11 |
8.1e-01 |
ACTR1A ELOVL7 FTSJ2 MGAT3 MPHOSPH9 RP11-261C10.5 ST3GAL3 |
Schizophrenia vs Biploar Disorder |
2.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Worry (Nagel 2018) |
1.98 |
7 |
3 |
6.7 |
0.01 |
9.9e-01 |
ACTR1A B3GALTL CADM2 CTC-498M16.2 DND1 RABGAP1L STK24 |
Crohns Disease (2017) |
1.78 |
6 |
4 |
8.9 |
0.66 |
1.1e-01 |
EIF3CL MST1R RBM6 RNF123 SNX32 TRAIP |
Irritable Bowel Disease (IBD) |
2.01 |
7 |
5 |
11.1 |
0.79 |
1.9e-02 |
EIF3CL MST1R RBM6 RBMS1 RNF123 TMED5 TRAIP |
Ulcerative Colitis (UC) |
1.84 |
5 |
4 |
8.9 |
0.80 |
5.3e-02 |
EIF3CL MST1R RBM6 RNF123 TRAIP |
Major Depression (MDD) |
1.98 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
NEGR1 TRMT61A |
Reaction Time |
1.76 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CYHR1 EXT1 FOXO3 |
Verbal and Numeric Reasoning (VNR) |
6.18 |
34 |
22 |
48.9 |
0.97 |
2.9e-23 |
AFF3 CALN1 CKM CYHR1 DCAF16 DND1 EIF3CL FAM160A1 FBXO41 FOXO3 FOXO6 FOXP1 IFT57 JMJD1C-AS1 LINC00461 LONRF2 MGAT3 MST1R NEGR1 NPM3 NR2F1-AS1 PPA2 RBL2 RBM6 RNF123 RPS26 SNX29 ST3GAL3 ST6GAL2 SYPL2 TANK TEX15 TRAIP TRMT61A |
Breast Cancer |
1.36 |
4 |
2 |
4.4 |
-0.54 |
4.6e-01 |
B3GNT1 DND1 METTL10 RP11-767N6.2 |
Ovarian Cancer |
1.29 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
DND1 |
Prostate Cancer |
1.83 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MDM4 PPA2 |
Age at First Birth |
3.75 |
5 |
4 |
8.9 |
1.00 |
1.6e-05 |
CYHR1 MST1R RBM6 RNF123 TRAIP |
Bipolar Disorder (2011) |
1.82 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
B3GNT1 |
Body Mass Index (BMI) (2010) |
2.46 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
EIF3CL NEGR1 TRIM73 |
Crohns Disease (2012) |
1.95 |
4 |
4 |
8.9 |
0.95 |
5.0e-02 |
EIF3CL MST1R RNF123 TRAIP |
HDL Cholesterol |
1.50 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 TCAP TMED5 |
LDL Cholesterol |
1.07 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
SYPL2 |
Neuroticism (2016) |
1.80 |
4 |
1 |
2.2 |
-0.66 |
3.4e-01 |
DND1 LINC00461 STK24 TANK |
Primary Biliary Cirrhosis |
1.26 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
DND1 TCAP |
Schizophrenia (2014) |
2.09 |
7 |
5 |
11.1 |
0.72 |
6.8e-02 |
ACTR1A C2orf82 FTSJ2 MGAT3 MPHOSPH9 RP11-261C10.5 STK4 |
Ulcerative Colitis |
1.72 |
4 |
2 |
4.4 |
0.99 |
7.3e-04 |
MST1R RBM6 RNF123 TRAIP |
Blood Eosinophil Count |
1.24 |
17 |
14 |
31.1 |
0.02 |
9.5e-01 |
ADD3 CACNA1H CCDC24 CKM DND1 GPX1 IL12RB1 INO80E MPHOSPH9 MST1R PRUNE RBM6 RP11-298I3.1 RPS26 SNX32 TMED5 TRAIP |
Blood Platelet Count |
1.41 |
25 |
19 |
42.2 |
-0.13 |
5.3e-01 |
ADD3 C18orf8 CKM DCAF16 DND1 EDEM3 EIF2C2 FAM160A1 GRK4 INO80E JMJD1C-AS1 LINC00461 METTL10 MPHOSPH9 MPP6 PRDX5 RP11-767N6.2 RP11-864G5.3 RRP7A SNX32 STAG3L5P-PVRIG2P-PILRB TCAP TMED5 TRMT61A WDR24 |
Blood Red Count |
1.41 |
17 |
12 |
26.7 |
-0.39 |
1.1e-01 |
AFF3 CEP57 CKM CTC-498M16.2 DND1 EFTUD1 EIF3CL INO80E LINC00461 MAP4 MPHOSPH9 RABGAP1L RP11-767N6.2 RPS26 TCAP TMED5 TRAIP |
Blood White Count |
1.51 |
28 |
19 |
42.2 |
-0.65 |
1.3e-04 |
ACTR1A ASCC2 C18orf8 CACNA1H CAMKMT CKM CTC-498M16.2 DCAF16 DND1 FAM160A1 FASTKD5 GRK4 INO80E JMJD1C-AS1 METTL10 MGAT3 MST1R PPA2 PRUNE RBM6 RNF123 RP11-864G5.3 RRP7A SEMA6D STAG3L5P-PVRIG2P-PILRB TEX15 TRAIP TRMT61A |
Heel T-Score |
1.29 |
20 |
16 |
35.6 |
-0.14 |
5.5e-01 |
ASCC2 C11orf83 C2orf82 DCAF16 DND1 IL12RB1 INO80E METTL10 MPHOSPH9 MST1R NEGR1 PROCR RAB11FIP4 RBM6 RP11-166B2.1 RP11-767N6.2 SNX32 STAG3L5P-PVRIG2P-PILRB TRAIP TRMT61A |
BMI |
3.92 |
41 |
27 |
60.0 |
-0.71 |
1.2e-07 |
ACTR1A C18orf8 CADM2 CPNE3 CTC-498M16.2 DOT1L EDEM3 EIF3CL FOXO3 FOXP1 GALNT16 GPX1 GRK4 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 MAP4 METTL10 MST1R NAT6 NEGR1 NR2F1-AS1 PKP4 PRDX5 PRUNE RBM6 RGS6 RNF123 RPS26 SNX32 STAG3L5P-PVRIG2P-PILRB STK24 SYPL2 TEX15 THEM6 TRAIP TRIM73 |
Height |
1.71 |
45 |
36 |
80.0 |
0.49 |
6.3e-04 |
AFF3 C18orf8 C2orf82 C9orf5 CACNA1H CAMKMT CCDC144B CEP57 COX6B1 CPNE3 DCAF16 DCP2 DND1 EIF2C2 ELOVL7 FAM160A1 FASTKD5 FOXO3 GGACT INO80E IST1 MDM4 METTL10 MGAT3 MPHOSPH9 MPP6 PPA2 PPP2R2D PROCR PRUNE RAB11FIP4 RBL2 RP11-1186N24.5 RP11-166B2.1 RP11-767N6.2 RP11-864G5.3 SNX32 ST3GAL3 STAG3L5P-PVRIG2P-PILRB STK4 TBCE TMED5 TRIM73 TRMT61A WDR24 |
Waist Hip Ratio (WHR) |
1.72 |
14 |
9 |
20.0 |
-0.95 |
1.2e-07 |
AFF3 C11orf83 C9orf5 CCDC144B DND1 GNL3LP1 IL12RB1 JUND MGAT3 MPHOSPH9 PRDX5 PROCR RBL2 SEMA6D |
Systolic Blood Pressure |
1.64 |
20 |
9 |
20.0 |
-0.28 |
1.9e-01 |
ACTR1A CCDC144B DCAF16 DND1 EDEM3 FBXO41 FOXO3 HERC4 HYI MAP4 MPP6 PPP2R2D PRDX5 RNF123 RP11-166B2.1 RP11-298I3.1 SNX32 ST6GAL2 TRAIP TRIM73 |
Smoking Status |
3.83 |
24 |
9 |
20.0 |
-0.87 |
1.2e-08 |
ACTR1A CADM2 CELF2 CKM DND1 EFTUD1 ELOVL7 FOXP1 GGACT GNL3LP1 IFT57 LONRF2 MAP4 MST1R NAT6 PTK2 RABGAP1L RP11-767N6.2 RPS26 SEMA6D SNX32 ST3GAL3 TANK WDR24 |
Allergy or Eczema |
1.41 |
6 |
2 |
4.4 |
0.71 |
1.1e-01 |
EIF3CL MPHOSPH9 NEGR1 PRUNE RPS26 TMED5 |
Cardiovascular Disease |
1.85 |
12 |
6 |
13.3 |
-0.57 |
5.5e-02 |
C18orf8 DCAF16 FBXO41 GRK4 LMOD1 MAP4 NEGR1 RBL2 RP11-261C10.5 SNX32 TEX15 TRIM73 |
Hypothyroidism (self reported) |
1.37 |
4 |
2 |
4.4 |
0.44 |
5.6e-01 |
JUND PTK2 RPS26 TANK |
Respiratory disease |
1.56 |
5 |
1 |
2.2 |
-0.47 |
4.2e-01 |
MST1R RABGAP1L RBM6 RPS26 TCAP |
Type 2 Diabetes (T2D) (2018) |
1.89 |
6 |
1 |
2.2 |
-0.75 |
5.4e-02 |
CYHR1 MST1R RBL2 RBM6 SNX32 TRAIP |
Lung FEV1/FVC ratio |
1.57 |
20 |
14 |
31.1 |
-0.12 |
6.1e-01 |
ACTR1A ADD3 AFF3 ASCC2 CCDC144B DND1 FOXO3 GPX1 IL12RB1 JMJD1C-AS1 JUND LMOD1 NEGR1 PPA2 RBMS1 RNF123 RP11-298I3.1 RP11-767N6.2 RPS26 STAG3L5P-PVRIG2P-PILRB |
Lung FVC |
1.87 |
20 |
13 |
28.9 |
0.19 |
4.2e-01 |
B3GNT1 C11orf83 C18orf8 CYHR1 DCAF16 DND1 EIF3CL FOXO3 FOXO6 FOXP1 JMJD1C-AS1 JUND MDM4 MPHOSPH9 MST1R NR2F1-AS1 PROCR RNF123 RPS26 TCAP |
Neuroticism |
2.34 |
9 |
5 |
11.1 |
-0.66 |
5.4e-02 |
B3GALTL CELF4 CTC-498M16.2 DND1 GALNT16 GPX1 LINC00461 RABGAP1L STK24 |
Chronotype (morning person) |
1.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MST1R |
Hair Pigment |
0.33 |
9 |
6 |
13.3 |
-0.40 |
2.9e-01 |
ADD3 B3GNT1 DND1 EXT1 FOXO3 JMJD1C-AS1 MPHOSPH9 PROCR RPS26 |
Tanning |
0.69 |
3 |
3 |
6.7 |
-0.08 |
9.2e-01 |
CADM2 IST1 PROCR |
Hand grip strength (left) |
1.83 |
10 |
5 |
11.1 |
0.02 |
9.5e-01 |
ACTR1A AFF3 CADM2 CALN1 DCAF16 DND1 FOXP1 NPM3 PROCR STAG3L5P-PVRIG2P-PILRB |
Number of treatments/medications taken |
2.97 |
11 |
4 |
8.9 |
-0.97 |
1.3e-07 |
B3GALTL DCAF16 FBXO41 MST1R PPP2R2D RABGAP1L RBM6 RNF123 ST6GAL2 TANK TRAIP |
Sensitivity / hurt feelings |
1.96 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CELF4 DND1 |
Frequency of depressed mood in last 2 weeks |
1.70 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
JMJD1C-AS1 |
Hearing difficulty/problems: Yes |
1.34 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
PTK2 RP11-767N6.2 |
Relative age of first facial hair |
2.12 |
4 |
1 |
2.2 |
-0.34 |
6.6e-01 |
DND1 FOXO3 PRUNE RABGAP1L |
Systolic blood pressure, automated reading |
1.91 |
12 |
4 |
8.9 |
-0.72 |
8.1e-03 |
DCAF16 DND1 EDEM3 FBXO41 MPP6 PKP4 PPA2 PROCR RNF123 RP11-298I3.1 SNX32 TRIM73 |
Medication: Co-codamol |
2.08 |
3 |
0 |
0.0 |
-1.00 |
1.2e-03 |
MST1R RBM6 RNF123 |
Pack years adult smoking proportion |
2.32 |
6 |
1 |
2.2 |
-0.16 |
7.7e-01 |
BNIP3 CELF4 GPX1 GRK4 JMJD1C-AS1 SEMA6D |
Impedance of leg (right) |
2.11 |
25 |
18 |
40.0 |
0.26 |
1.9e-01 |
ACTR1A B3GNT1 EIF3CL FAM160A1 INO80E JUND LINC00461 LMOD1 MST1R NAT6 NEGR1 PPA2 PTK2 RBL2 RBM6 RBMS1 RGS6 RNF123 RPS26 SEMA6D SLC35A1 SNX32 STAG3L5P-PVRIG2P-PILRB SYPL2 TRIM73 |
Leg fat-free mass (left) |
2.64 |
29 |
23 |
51.1 |
-0.31 |
9.9e-02 |
ACTR1A C18orf8 C9orf5 CADM2 CTC-498M16.2 DCAF16 EIF3CL FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PRDX5 PROCR RBL2 RBM6 RNF123 RPS26 SNX32 SYPL2 TRAIP TRIM38 TRIM73 |
Trunk fat percentage |
3.10 |
27 |
18 |
40.0 |
-0.67 |
1.1e-04 |
C11orf83 C18orf8 CADM2 DND1 EDEM3 EIF3CL FOXO3 FOXP1 GALNT16 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MPP6 MST1R NEGR1 RBM6 RNF123 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Hand grip strength (right) |
1.76 |
7 |
4 |
8.9 |
0.27 |
5.6e-01 |
ACTR1A DCAF16 DND1 EIF3CL NPM3 PROCR STAG3L5P-PVRIG2P-PILRB |
Current tobacco smoking |
2.80 |
4 |
2 |
4.4 |
-0.98 |
2.4e-02 |
ACTR1A CADM2 SEMA6D ST3GAL3 |
Maternal smoking around birth |
2.78 |
5 |
1 |
2.2 |
-0.93 |
2.0e-02 |
ACTR1A ARTN CKM MST1R NAT6 |
Fed-up feelings |
3.36 |
13 |
5 |
11.1 |
-0.87 |
5.6e-05 |
B3GNT1 CELF4 DND1 GALNT16 GPX1 LINC00461 LONRF2 MST1R PRDX5 RBM6 RNF123 THEM6 TRAIP |
Frequency of unenthusiasm / disinterest in last 2 weeks |
2.53 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
GALNT16 JMJD1C-AS1 |
Relative age voice broke |
1.87 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
DND1 FOXO3 |
Taking other prescription medications |
2.48 |
5 |
4 |
8.9 |
-1.00 |
2.5e-05 |
B3GALTL MST1R RBM6 RNF123 TRAIP |
Age when periods started (menarche) |
2.74 |
13 |
9 |
20.0 |
-0.44 |
9.1e-02 |
C9orf5 COX6B1 FOXO3 HYI INO80E MST1R NAT6 NEGR1 RNF123 RRP7A SNX32 ST3GAL3 TRIM73 |
Heel bone mineral density (BMD) T-score, automated (left) |
1.10 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
MST1R PROCR TRAIP |
Qualifications: CSEs or equivalent |
3.09 |
3 |
0 |
0.0 |
-0.68 |
3.2e-01 |
FOXO6 MST1R RNF123 |
High blood pressure |
1.80 |
9 |
1 |
2.2 |
-0.36 |
3.4e-01 |
DCAF16 FBXO41 NEGR1 PTK2 RBL2 RP11-261C10.5 SNX32 TEX15 TRIM73 |
Hayfever, allergic rhinitis or eczema |
1.37 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MPHOSPH9 RPS26 |
Medication: Levothyroxine sodium |
1.21 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RPS26 |
Sitting height |
1.91 |
15 |
11 |
24.4 |
0.83 |
1.5e-04 |
C2orf82 DCAF16 DND1 EIF2C2 FOXO3 MGAT3 MPHOSPH9 PPA2 PPP2R2D PROCR RBL2 RP11-767N6.2 SLC35A1 TRIM38 WDR24 |
Body mass index (BMI) |
4.08 |
34 |
21 |
46.7 |
-0.79 |
1.2e-08 |
ACTR1A C18orf8 CADM2 CPNE3 CTC-498M16.2 DOT1L EDEM3 EIF3CL FOXO3 FOXP1 GPX1 GRK4 IFT57 IL12RB1 INO80E LINC00461 LMOD1 LONRF2 MAP4 MPP6 MST1R NAT6 NEGR1 PKP4 RBM6 RBMS1 RGS6 RNF123 RPS26 SNX32 STK24 TEX15 TRAIP TRIM73 |
Impedance of leg (left) |
2.15 |
25 |
19 |
42.2 |
0.26 |
2.0e-01 |
ACTR1A B3GNT1 EIF3CL FAM160A1 INO80E JUND LINC00461 LMOD1 MST1R NAT6 NEGR1 PPA2 PTK2 RBL2 RBM6 RBMS1 RGS6 RNF123 RPS26 SEMA6D SLC35A1 SNX32 STAG3L5P-PVRIG2P-PILRB SYPL2 TRIM73 |
Leg predicted mass (left) |
2.65 |
29 |
23 |
51.1 |
-0.30 |
1.0e-01 |
ACTR1A C18orf8 C9orf5 CADM2 CTC-498M16.2 DCAF16 EIF3CL FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PRDX5 PROCR RBL2 RBM6 RNF123 RPS26 SNX32 SYPL2 TRAIP TRIM38 TRIM73 |
Trunk fat mass |
3.23 |
26 |
20 |
44.4 |
-0.72 |
1.9e-05 |
C18orf8 CADM2 CTC-498M16.2 EIF3CL FOXO3 FOXP1 GALNT16 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MST1R NEGR1 PRDX5 RBM6 RGS6 RNF123 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Waist circumference |
3.50 |
26 |
19 |
42.2 |
-0.74 |
8.6e-06 |
C18orf8 C9orf5 CADM2 CTC-498M16.2 EIF3CL FOXO3 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MST1R NAT6 NEGR1 RBM6 RGS6 RNF123 RPS26 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Number of incorrect matches in round |
1.94 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
EXT1 INO80E NPM3 |
Past tobacco smoking |
2.80 |
9 |
2 |
4.4 |
0.79 |
6.6e-03 |
ACTR1A C18orf8 CADM2 CYHR1 GGACT MAP4 NAT6 TANK WDR24 |
Alcohol usually taken with meals |
4.33 |
11 |
4 |
8.9 |
0.97 |
2.9e-08 |
ACTR1A ARTN CADM2 CELF4 ELOVL7 FOXP1 GNL3LP1 HYI LONRF2 NEGR1 RABGAP1L |
Nervous feelings |
1.80 |
7 |
4 |
8.9 |
0.17 |
6.8e-01 |
ACTR1A B3GALTL CADM2 CTC-498M16.2 DND1 INO80E STK24 |
Frequency of tenseness / restlessness in last 2 weeks |
1.98 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
B3GALTL DND1 MST1R |
Hair/balding pattern: Pattern 2 |
1.07 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GGACT |
Had other major operations |
1.75 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PPA2 |
Forced vital capacity (FVC) |
1.93 |
11 |
5 |
11.1 |
0.63 |
3.7e-02 |
C11orf83 DCAF16 DND1 FOXP1 IST1 MDM4 MST1R PPA2 PPP2R2D RBL2 RNF123 |
Heel bone mineral density (BMD) T-score, automated (right) |
1.12 |
4 |
0 |
0.0 |
-0.83 |
1.7e-01 |
DCAF16 MST1R PROCR TRAIP |
Ever unenthusiastic/disinterested for a whole week |
1.51 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DND1 |
Qualifications: None of the above |
9.28 |
57 |
33 |
73.3 |
-0.98 |
3.2e-45 |
ACTR1A AFF3 ARTN B3GALTL B3GNT1 BNIP3 C9orf5 CCDC24 CELF2 CELF4 CEP57 CKM CTC-498M16.2 DNAH11 EIF3CL ELOVL7 FAM160A1 FOXO3 FOXP1 FPGT FTSJ2 GNL3LP1 GPX1 GRK4 HYI IFT57 IST1 JMJD1C-AS1 LONRF2 MAN2A1 MAP4 MPHOSPH9 MPP6 MST1R NAT6 NEGR1 NPM3 NR2F1-AS1 PPA2 PPP2R2D RBL2 RBM6 RNF123 RP11-261C10.5 RPS26 SLC35A1 SNX29 ST3GAL3 ST6GAL2 SYPL2 TANK TEX15 THEM6 TMED5 TRAIP TRIM38 WDR24 |
Mouth/teeth dental problems |
2.13 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
DND1 RP11-261C10.5 |
Allergy |
1.39 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
AFF3 MPHOSPH9 RPS26 |
Diabetes (self-reported) |
1.99 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBL2 RBM6 TRAIP |
Hayfever/allergic rhinitis (self-reported) |
1.37 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RPS26 |
Fluid intelligence score |
6.49 |
39 |
20 |
44.4 |
0.98 |
4.9e-29 |
AFF3 ARTN BNIP3 C20orf197 CALN1 CCDC24 CKM CTD-3025N20.2 CYHR1 DCAF16 DND1 EIF3CL FAM160A1 FBXO41 FOXO3 FOXO6 FOXP1 HYI IFT57 JMJD1C-AS1 LONRF2 MGAT3 MPHOSPH9 MST1R NEGR1 NPM3 NR2F1-AS1 PPA2 RBL2 RBM6 RNF123 RPS26 ST3GAL3 ST6GAL2 STAG3L5P-PVRIG2P-PILRB SYPL2 TANK TRAIP TRMT61A |
Illnesses of siblings |
1.72 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
RBL2 |
Neuroticism score |
2.40 |
8 |
4 |
8.9 |
-0.78 |
2.3e-02 |
B3GALTL CELF4 DND1 GALNT16 GPX1 LINC00461 RABGAP1L STK24 |
Weight |
3.25 |
30 |
22 |
48.9 |
-0.59 |
5.4e-04 |
ACTR1A C18orf8 C9orf5 CADM2 CTC-498M16.2 DCAF16 EIF3CL FOXO3 IFT57 INO80E LINC00461 LMOD1 LONRF2 METTL10 MPHOSPH9 MST1R NAT6 NEGR1 PRDX5 PROCR RBL2 RBM6 RNF123 RPS26 SNX32 TEX15 THEM6 TRAIP TRIM38 TRIM73 |
Impedance of arm (right) |
2.67 |
28 |
21 |
46.7 |
0.67 |
4.6e-05 |
ACTR1A C11orf83 CADM2 CTC-498M16.2 DND1 ELOVL7 FOXO3 GATC GPX1 INO80E JMJD1C-AS1 JUND LMOD1 MST1R NAT6 NEGR1 PRUNE RBM6 RBMS1 RGS6 RNF123 RP11-864G5.3 RPS26 SNX32 STAG3L5P-PVRIG2P-PILRB SYPL2 TRAIP TRIM73 |
Arm fat percentage (right) |
3.42 |
32 |
20 |
44.4 |
-0.72 |
2.5e-06 |
C11orf83 C18orf8 CADM2 CTC-498M16.2 DCAF16 EDEM3 EIF3CL FOXO3 FOXP1 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 MAP4 METTL10 MPP6 MST1R NEGR1 PKP4 RBM6 RGS6 RNF123 SEMA6D SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Trunk fat-free mass |
2.49 |
27 |
20 |
44.4 |
-0.18 |
3.7e-01 |
ACTR1A C18orf8 CADM2 CTC-498M16.2 DCAF16 EIF3CL ELOVL7 FAM160A1 FOXO3 GNL3LP1 INO80E LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 PPA2 PROCR RBL2 RBM6 RNF123 RPS26 SYPL2 TRAIP TRIM38 TRMT61A WDR24 |
Hip circumference |
2.81 |
25 |
18 |
40.0 |
-0.53 |
5.5e-03 |
ACTR1A C18orf8 CADM2 CTC-498M16.2 DCAF16 EIF3CL FOXO3 INO80E LINC00461 LMOD1 LONRF2 METTL10 MPHOSPH9 MST1R NAT6 NEGR1 PRDX5 RBL2 RBM6 RNF123 SNX32 THEM6 TRAIP TRIM38 TRIM73 |
Alcohol intake versus 10 years previously |
3.27 |
7 |
4 |
8.9 |
-0.71 |
3.1e-02 |
ARTN CCDC24 MST1R NEGR1 RBM6 RNF123 TRAIP |
Father's age at death |
2.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RNF123 |
Worrier / anxious feelings |
1.96 |
4 |
1 |
2.2 |
0.09 |
9.1e-01 |
ACTR1A B3GALTL CADM2 DND1 |
Frequency of tiredness / lethargy in last 2 weeks |
2.01 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GALNT16 JMJD1C-AS1 |
Falls in the last year |
1.45 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TCAP |
Hair/balding pattern: Pattern 3 |
1.64 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
DND1 GGACT |
Number of live births |
2.44 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 |
Forced expiratory volume in 1-second (FEV1) |
2.09 |
12 |
8 |
17.8 |
0.54 |
6.7e-02 |
C11orf83 DCAF16 DND1 FOXP1 GPX1 MDM4 MST1R PPA2 PPP2R2D RNF123 RPS26 TRIM38 |
Pulse rate |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBL2 |
Qualifications: A levels/AS levels or equivalent |
8.53 |
53 |
20 |
44.4 |
0.99 |
3.6e-49 |
ACTR1A ARTN CADM2 CAMKMT CCDC24 CELF2 CEP57 CKM COX6B1 CPNE3 CTD-3025N20.2 DCAF16 DDX31 DND1 ELOVL7 FAM160A1 FASTKD5 FBXO41 FOXO6 FTSJ2 GNL3LP1 HYI IFT57 JMJD1C-AS1 JUND LONRF2 MAP4 MGAT3 MPHOSPH9 MPP6 MST1R NEGR1 NOVA1 NPM3 PPA2 RAB11FIP4 RBL2 RBM6 RNF123 RP11-261C10.5 RPS26 RRP7A SNX29 ST3GAL3 ST6GAL2 TANK THEM6 TMED5 TRAIP TRIM38 TRIM73 TRMT61A WDR24 |
Mouth/teeth dental problems: Dentures |
2.86 |
6 |
2 |
4.4 |
-0.99 |
1.2e-05 |
INO80E MST1R NOVA1 RBM6 RNF123 TMED5 |
Asthma |
1.60 |
4 |
3 |
6.7 |
0.18 |
8.2e-01 |
AFF3 RPS26 TCAP TRIM38 |
Forced expiratory volume in 1-second (FEV1), Best measure |
2.15 |
11 |
7 |
15.6 |
0.47 |
1.4e-01 |
C11orf83 DCAF16 DND1 FOXP1 GPX1 MDM4 MST1R PPA2 RNF123 RPS26 TRIM38 |
Impedance of arm (left) |
2.60 |
25 |
22 |
48.9 |
0.75 |
6.0e-06 |
ACTR1A C11orf83 CADM2 CTC-498M16.2 DND1 FOXO3 GPX1 INO80E JMJD1C-AS1 JUND LMOD1 MST1R NAT6 NEGR1 PRUNE RBM6 RBMS1 RNF123 RP11-864G5.3 RPS26 SNX32 STAG3L5P-PVRIG2P-PILRB SYPL2 TRAIP TRIM73 |
Arm fat mass (right) |
3.72 |
30 |
20 |
44.4 |
-0.75 |
1.1e-06 |
C18orf8 CADM2 CTC-498M16.2 EDEM3 EIF3CL FOXO3 FOXP1 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 MAP4 METTL10 MST1R NAT6 NEGR1 PRDX5 RBM6 RGS6 RNF123 RPS26 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Trunk predicted mass |
2.49 |
28 |
20 |
44.4 |
-0.15 |
4.5e-01 |
ACTR1A C18orf8 CADM2 CTC-498M16.2 DCAF16 EIF3CL ELOVL7 FAM160A1 FOXO3 GNL3LP1 INO80E LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RPS26 SYPL2 TRAIP TRIM38 TRMT61A WDR24 |
Standing height |
1.83 |
27 |
16 |
35.6 |
0.67 |
1.4e-04 |
AFF3 C18orf8 C2orf82 CACNA1H CCDC144B DCAF16 DND1 EIF2C2 FAM160A1 FOXO3 GGACT GRK4 MPHOSPH9 MPP6 PPA2 PPP2R2D PROCR RAB11FIP4 RBL2 RP11-767N6.2 RRP7A SNX32 STAG3L5P-PVRIG2P-PILRB TBCE TRIM38 TRIM73 WDR24 |
Exposure to tobacco smoke at home |
1.99 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MST1R RNF123 |
Breastfed as a baby |
1.87 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MPHOSPH9 |
Tense / 'highly strung' |
1.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RABGAP1L |
Seen doctor (GP) for nerves, anxiety, tension or depression |
2.19 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
B3GALTL CELF4 NEGR1 |
Hair/balding pattern: Pattern 4 |
1.37 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
DND1 METTL10 |
Birth weight of first child |
1.98 |
6 |
3 |
6.7 |
0.60 |
2.1e-01 |
DCAF16 PPA2 PTK2 RP11-864G5.3 RPS26 TRIM73 |
Peak expiratory flow (PEF) |
1.53 |
5 |
2 |
4.4 |
0.70 |
1.9e-01 |
DCAF16 DND1 FOXO3 MDM4 NR2F1-AS1 |
Ever highly irritable/argumentative for 2 days |
2.26 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MST1R RBM6 |
Qualifications: O levels/GCSEs or equivalent |
4.41 |
8 |
1 |
2.2 |
0.95 |
3.4e-04 |
CKM FTSJ2 IFT57 MPHOSPH9 MPP6 MST1R RNF123 THEM6 |
Blood clot in the leg (DVT) |
1.15 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PROCR |
Medication: Paracetamol |
2.39 |
5 |
3 |
6.7 |
-0.99 |
1.0e-03 |
DND1 PTK2 RABGAP1L RP11-261C10.5 TMED5 |
Headache pain in last month |
1.66 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
DND1 RP11-261C10.5 RPS26 |
Hypothyroidism/myxoedema (self-reported) |
1.23 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
RPS26 TANK |
Medication: Ventolin 100micrograms inhaler |
1.64 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
AFF3 RPS26 |
Birth weight |
1.81 |
5 |
2 |
4.4 |
0.78 |
1.2e-01 |
DCAF16 PPA2 PTK2 RP11-864G5.3 SLC35A1 |
Chronic bronchitis/emphysema (mother) |
1.70 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MST1R |
Forced vital capacity (FVC), Best measure |
2.03 |
11 |
5 |
11.1 |
0.58 |
6.3e-02 |
C11orf83 DCAF16 DND1 FOXP1 IST1 MDM4 MST1R PPA2 RBL2 RNF123 TRIM38 |
Body fat percentage |
3.57 |
32 |
20 |
44.4 |
-0.75 |
4.1e-07 |
C11orf83 C18orf8 CADM2 CTC-498M16.2 DCAF16 EDEM3 EIF3CL FOXO3 FOXP1 GALNT16 GRK4 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MPP6 MST1R NEGR1 PKP4 RBM6 RGS6 RNF123 RP11-121L10.3 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Leg fat percentage (right) |
4.21 |
36 |
23 |
51.1 |
-0.81 |
9.0e-10 |
AFF3 BNIP3 C18orf8 CADM2 CPNE3 CTC-498M16.2 DCAF16 EDEM3 EIF3CL FOXO3 FOXP1 GALNT16 GPX1 GRK4 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MPP6 MST1R NEGR1 PKP4 RBM6 RGS6 RNF123 RP11-767N6.2 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Arm fat-free mass (right) |
2.83 |
29 |
22 |
48.9 |
-0.33 |
7.0e-02 |
ACTR1A C18orf8 CADM2 CTC-498M16.2 DCAF16 EIF3CL ELOVL7 FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RP11-864G5.3 RPS26 SNX32 SYPL2 TRAIP TRIM38 TRMT61A |
Exposure to tobacco smoke outside home |
2.50 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ELOVL7 MST1R |
Comparative body size at age 10 |
2.22 |
10 |
5 |
11.1 |
-0.29 |
3.9e-01 |
C18orf8 CADM2 CTC-498M16.2 EIF3CL FPGT MAP4 NAT6 NEGR1 PRUNE TNNI3K |
Worry too long after embarrassment |
1.66 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DND1 |
Seen a psychiatrist for nerves, anxiety, tension or depression |
1.48 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TRMT61A |
Wheeze or whistling in the chest in last year |
2.59 |
8 |
3 |
6.7 |
-0.98 |
3.2e-06 |
AFF3 DOT1L MAP4 MST1R RABGAP1L RBM6 RNF123 TRAIP |
Number of children fathered |
1.71 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 |
Reason for reducing amount of alcohol drunk: Health precaution |
1.69 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTC-498M16.2 |
Age at first live birth |
5.11 |
13 |
5 |
11.1 |
0.99 |
9.2e-13 |
ARTN C20orf197 CCDC24 CELF4 CEP57 CPNE3 DCAF16 GPX1 MST1R RBM6 RNF123 RPS26 TRAIP |
Health satisfaction |
1.93 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LMOD1 |
Shortness of breath walking on level ground |
1.82 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C18orf8 |
Medication for pain relief, constipation, heartburn |
2.37 |
7 |
1 |
2.2 |
0.99 |
6.7e-06 |
CEP57 DND1 MPHOSPH9 PTK2 RABGAP1L RP11-261C10.5 ST6GAL2 |
Neck or shoulder pain in last month |
2.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RPS26 |
Medication: Blood pressure |
1.92 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCAF16 FBXO41 MAP4 |
Mean time to correctly identify matches |
1.73 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
CYHR1 FOXO3 IFT57 |
Whole body fat mass |
3.67 |
28 |
21 |
46.7 |
-0.76 |
1.6e-06 |
C18orf8 CADM2 CTC-498M16.2 EDEM3 EIF3CL FOXO3 FOXP1 GALNT16 GPX1 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MST1R NEGR1 RBM6 RGS6 RNF123 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Leg fat mass (right) |
4.14 |
33 |
22 |
48.9 |
-0.79 |
2.0e-08 |
ACTR1A C18orf8 CADM2 CPNE3 CTC-498M16.2 EDEM3 EIF3CL FOXO3 FOXP1 GALNT16 GPX1 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MPP6 MST1R NAT6 NEGR1 RBM6 RGS6 RNF123 RPS26 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Arm predicted mass (right) |
2.86 |
29 |
21 |
46.7 |
-0.34 |
6.3e-02 |
ACTR1A C18orf8 CADM2 CTC-498M16.2 DCAF16 EIF3CL ELOVL7 FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RP11-864G5.3 RPS26 SNX32 SYPL2 TRAIP TRIM38 TRMT61A |
Pulse rate, automated reading |
1.65 |
11 |
5 |
11.1 |
-0.29 |
3.5e-01 |
CTC-498M16.2 HYI LINC00461 MST1R NEGR1 RABGAP1L RBL2 RBM6 RP11-864G5.3 TRAIP TRIM73 |
Alcohol intake frequency. |
3.67 |
17 |
10 |
22.2 |
-0.93 |
2.4e-08 |
BNIP3 C18orf8 CCDC144B CTC-498M16.2 DND1 EIF3CL FOXP1 GALNT16 INO80E IST1 MPHOSPH9 MST1R RBM6 RBMS1 STAG3L5P-PVRIG2P-PILRB TEX15 TRAIP |
Comparative height size at age 10 |
1.83 |
21 |
14 |
31.1 |
0.26 |
2.6e-01 |
ARTN C18orf8 CCDC144B DCAF16 DND1 EIF3CL FAM160A1 FOXO3 HYI INO80E JUND METTL10 MPHOSPH9 PROCR RAB11FIP4 RBL2 RP11-767N6.2 ST3GAL3 TMED5 TRIM38 WDR24 |
Number of full sisters |
2.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 |
Suffer from 'nerves' |
1.61 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
EIF3CL |
Overall health rating |
4.42 |
22 |
11 |
24.4 |
-0.97 |
1.7e-14 |
B3GALTL CKM DOT1L EIF2C2 FASTKD5 FOXP1 GALNT16 GPX1 GRK4 LMOD1 MST1R RABGAP1L RBL2 RBM6 RGS6 RNF123 RP11-261C10.5 SNX32 TANK TEX15 THEM6 TRAIP |
Age at last live birth |
3.78 |
6 |
4 |
8.9 |
0.99 |
6.8e-06 |
LONRF2 MST1R NAT6 RBM6 RNF123 TRAIP |
Leg pain on walking |
2.50 |
4 |
1 |
2.2 |
-1.00 |
1.6e-04 |
MST1R RBM6 RNF123 TRAIP |
Qualifications: NVQ or HND or HNC or equivalent |
2.64 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBM6 |
Knee pain experienced in last month |
2.35 |
5 |
0 |
0.0 |
-0.97 |
7.4e-03 |
MST1R PROCR PTK2 RBM6 RP11-261C10.5 |
Hypertension (Self-reported) |
1.77 |
10 |
2 |
4.4 |
-0.55 |
9.8e-02 |
DCAF16 FBXO41 LMOD1 MAP4 NEGR1 RBL2 RP11-261C10.5 SNX32 TEX15 TRIM73 |
Smoking status: Previous |
2.26 |
3 |
1 |
2.2 |
-0.65 |
3.5e-01 |
C18orf8 CADM2 CYHR1 |
Forced expiratory volume in 1-second (FEV1), predicted |
1.41 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
DCAF16 |
Whole body fat-free mass |
2.60 |
31 |
22 |
48.9 |
-0.22 |
2.3e-01 |
ACTR1A C18orf8 C9orf5 CADM2 CTC-498M16.2 DCAF16 EIF3CL ELOVL7 FAM160A1 FOXO3 GNL3LP1 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RPS26 SNX32 SYPL2 TRAIP TRIM38 TRMT61A WDR24 |
Leg fat-free mass (right) |
2.56 |
31 |
23 |
51.1 |
-0.23 |
2.1e-01 |
ACTR1A C18orf8 C9orf5 CACNA1H CADM2 CTC-498M16.2 DCAF16 EIF3CL FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RPS26 SLC35A1 SNX32 SYPL2 TRAIP TRIM38 TRIM73 WDR24 |
Arm fat percentage (left) |
3.39 |
30 |
21 |
46.7 |
-0.76 |
8.1e-07 |
C18orf8 CADM2 CTC-498M16.2 DCAF16 EDEM3 EIF3CL FOXP1 GRK4 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 MAP4 METTL10 MPP6 MST1R NEGR1 PKP4 RBM6 RGS6 RNF123 SEMA6D SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Average weekly red wine intake |
3.76 |
7 |
2 |
4.4 |
0.90 |
5.2e-03 |
B3GNT1 C18orf8 CEP57 CTC-498M16.2 FOXP1 MPHOSPH9 TMED5 |
Handedness (chirality/laterality): Left-handed |
1.39 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DND1 |
Mood swings |
2.83 |
9 |
3 |
6.7 |
-0.90 |
4.2e-04 |
CELF2 CELF4 DND1 GPX1 MST1R PTK2 RBM6 RNF123 STK24 |
Loneliness, isolation |
2.10 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
JMJD1C-AS1 |
Long-standing illness, disability or infirmity |
2.13 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NEGR1 NR2F1-AS1 |
Ever had bowel cancer screening |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TRAIP |
Diabetes diagnosed by doctor |
1.83 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBL2 RBM6 |
Friendships satisfaction |
1.81 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C18orf8 CEP57 |
Qualifications: nursing, teaching |
6.04 |
13 |
5 |
11.1 |
0.97 |
2.1e-09 |
ARTN CADM2 ELOVL7 GALNT16 JMJD1C-AS1 METTL10 MPHOSPH9 MST1R NEGR1 PPA2 RBM6 STK24 TRAIP |
Mouth/teeth dental problems: Mouth ulcers |
1.41 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
CEP57 DND1 IL12RB1 |
Medication for cholesterol |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RBL2 |
Back pain experienced in last month |
2.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PTK2 |
Mineral and other dietary supplements |
1.62 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTC-498M16.2 GRK4 |
Asthma (self-reported) |
1.60 |
4 |
2 |
4.4 |
0.17 |
8.3e-01 |
AFF3 RPS26 TCAP TRIM38 |
Smoking status: Current |
2.78 |
4 |
4 |
8.9 |
-0.99 |
1.4e-02 |
ACTR1A CADM2 SEMA6D ST3GAL3 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.77 |
5 |
2 |
4.4 |
0.58 |
3.0e-01 |
C11orf83 DND1 INO80E PPA2 RNF123 |
Whole body water mass |
2.63 |
31 |
22 |
48.9 |
-0.22 |
2.3e-01 |
ACTR1A C18orf8 C9orf5 CADM2 CTC-498M16.2 DCAF16 EIF3CL ELOVL7 FAM160A1 FOXO3 GNL3LP1 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RPS26 SNX32 SYPL2 TRAIP TRIM38 TRMT61A WDR24 |
Leg predicted mass (right) |
2.55 |
31 |
22 |
48.9 |
-0.23 |
2.1e-01 |
ACTR1A C18orf8 C9orf5 CACNA1H CADM2 CTC-498M16.2 DCAF16 EIF3CL FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RPS26 SLC35A1 SNX32 SYPL2 TRAIP TRIM38 TRIM73 WDR24 |
Arm fat mass (left) |
3.68 |
30 |
20 |
44.4 |
-0.75 |
1.2e-06 |
C18orf8 CADM2 CTC-498M16.2 EDEM3 EIF3CL FOXO3 FOXP1 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 MAP4 METTL10 MST1R NAT6 NEGR1 PRDX5 RBM6 RGS6 RNF123 RPS26 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Number of self-reported non-cancer illnesses |
2.02 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
FBXO41 NEGR1 |
Average weekly champagne plus white wine intake |
2.80 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
DND1 WDR24 |
Miserableness |
2.90 |
11 |
6 |
13.3 |
-0.96 |
1.3e-06 |
B3GALTL CELF2 CELF4 DND1 FTSJ2 GPX1 MST1R RABGAP1L RBM6 RNF123 RP11-261C10.5 |
Financial situation satisfaction |
2.12 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
RNF123 |
Commuting to job workplace: Public transport |
2.63 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
LONRF2 |
Supplements: Fish oil (including cod liver oil) |
1.66 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
B3GNT1 GRK4 |
High cholesterol (Self-reported) |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCAF16 |
Medication: Bendroflumethiazide |
1.42 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
TEX15 |
Medication: Paracetamol |
2.43 |
4 |
1 |
2.2 |
-0.99 |
1.0e-02 |
DND1 PTK2 RABGAP1L RP11-261C10.5 |
Ever smoked |
2.53 |
7 |
2 |
4.4 |
-0.74 |
3.4e-02 |
ACTR1A C18orf8 CADM2 GGACT GNL3LP1 MAP4 WDR24 |
Basal metabolic rate |
2.76 |
28 |
23 |
51.1 |
-0.33 |
7.7e-02 |
ACTR1A C18orf8 C9orf5 CADM2 CTC-498M16.2 DCAF16 EIF3CL FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RPS26 SNX32 SYPL2 TRAIP TRIM38 TRIM73 |
Leg fat percentage (left) |
4.24 |
35 |
26 |
57.8 |
-0.81 |
1.6e-09 |
BNIP3 C18orf8 CADM2 CPNE3 CTC-498M16.2 DCAF16 EDEM3 EIF3CL FOXO3 FOXP1 GALNT16 GPX1 GRK4 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MPP6 MST1R NEGR1 PKP4 RBM6 RGS6 RNF123 RP11-767N6.2 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Arm fat-free mass (left) |
2.88 |
28 |
21 |
46.7 |
-0.37 |
4.6e-02 |
ACTR1A C18orf8 CADM2 CTC-498M16.2 DCAF16 EIF3CL ELOVL7 FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RP11-864G5.3 RPS26 SNX32 TRAIP TRIM38 TRMT61A |
Number of operations (self-reported) |
1.95 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MST1R |
Average weekly beer plus cider intake |
3.09 |
5 |
4 |
8.9 |
-0.98 |
4.4e-04 |
CELF4 MST1R RBM6 RNF123 TRAIP |
Irritability |
1.68 |
4 |
2 |
4.4 |
-0.18 |
8.2e-01 |
CELF4 DND1 LINC00461 TRMT61A |
Risk taking |
1.83 |
3 |
1 |
2.2 |
-0.66 |
3.4e-01 |
CADM2 FAM160A1 RP11-261C10.5 |
Ever had prostate specific antigen (PSA) test |
1.17 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTC-498M16.2 |
Diastolic blood pressure, automated reading |
2.48 |
17 |
10 |
22.2 |
-0.76 |
2.5e-04 |
DCAF16 EDEM3 FBXO41 LINC00461 LMOD1 MAP4 MPHOSPH9 MPP6 MST1R PKP4 RBM6 RNF123 RP11-261C10.5 RP11-298I3.1 SNX32 TRAIP TRIM73 |
Unable to work because of sickness or disability |
2.29 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DOT1L |
Myopia |
1.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
GGACT |
Vascular/heart problems diagnosed by doctor |
1.89 |
8 |
1 |
2.2 |
0.60 |
1.1e-01 |
DCAF16 FBXO41 LMOD1 NEGR1 RBL2 RP11-261C10.5 SNX32 TEX15 |
Cholesterol lowering medication |
1.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
DCAF16 |
Pain experienced in last month |
2.97 |
6 |
1 |
2.2 |
0.97 |
3.6e-04 |
DND1 MST1R PTK2 RBM6 RNF123 RPS26 |
Deep venous thrombosis (DVT) (self-reported) |
1.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PROCR |
Pack years of smoking |
2.19 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
JMJD1C-AS1 |
Impedance of whole body |
2.46 |
30 |
22 |
48.9 |
0.51 |
3.1e-03 |
ACTR1A C11orf83 CADM2 CTC-498M16.2 DND1 ELOVL7 FOXO3 GPX1 INO80E JMJD1C-AS1 JUND LINC00461 LMOD1 MST1R NAT6 NEGR1 PPA2 PROCR PRUNE PTK2 RBM6 RBMS1 RGS6 RNF123 RPS26 SNX32 STAG3L5P-PVRIG2P-PILRB SYPL2 TRAIP TRIM73 |
Leg fat mass (left) |
4.16 |
33 |
21 |
46.7 |
-0.79 |
2.0e-08 |
ACTR1A C18orf8 CADM2 CPNE3 CTC-498M16.2 EDEM3 EIF3CL FOXO3 FOXP1 GALNT16 GPX1 IFT57 IL12RB1 INO80E JUND LINC00461 LMOD1 LONRF2 METTL10 MPP6 MST1R NAT6 NEGR1 RBM6 RGS6 RNF123 RPS26 SNX32 STK24 TEX15 THEM6 TRAIP TRIM73 |
Arm predicted mass (left) |
2.90 |
28 |
21 |
46.7 |
-0.37 |
4.6e-02 |
ACTR1A C18orf8 CADM2 CTC-498M16.2 DCAF16 EIF3CL ELOVL7 FAM160A1 FOXO3 INO80E LINC00461 LMOD1 MGAT3 MPHOSPH9 MST1R NAT6 NEGR1 PPA2 PROCR RBL2 RBM6 RNF123 RP11-864G5.3 RPS26 SNX32 TRAIP TRIM38 TRMT61A |